Biomarkers to optimize the treatment of nicotine dependence
- PMID: 22103610
- PMCID: PMC3285251
- DOI: 10.2217/bmm.11.91
Biomarkers to optimize the treatment of nicotine dependence
Abstract
The application of genomic medicine to the treatment of nicotine dependence holds great promise for revitalizing the steady decline in smoking rates witnessed in the USA over the past several decades. This paper examines the current knowledge base concerning the use of biomarkers to guide the selection of nicotine dependence treatments. First, we review the neurobiology of nicotine dependence and present evidence that supports its heritability. We then discuss the various studies of pharmacokinetic and pharmacodynamic genes related to therapeutic response. Current evidence suggests that biomarkers of genetic variability in both nicotine metabolism, referred to as the nicotine metabolite ratio, and dopamine genotypes may be useful for guiding treatment selection for nicotine dependence. Barriers to the translation of this research to clinical practice are discussed, as are directions for future research.
References
-
- Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. MMWR Morb Mortal Wkly Rep. 2008;57:1226–1228. - PubMed
-
- United States Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; Atlanta, GA, USA: 2004.
-
- Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥18 years – United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:1135–1140. - PubMed
-
- Centers for Disease Control and Prevention. Cigarette smoking – United States, 1965–2008. MMWR Morb Mortal Wkly Rep. 2011;60:109–113.
-
- Levy DT, Mabry PL, Graham AL, Orleans CT, Abrams DB. Exploring scenarios to dramatically reduce smoking prevalence: a simulation model of the three-part cessation process. Am J Public Health. 2010;100:1253–1259. Reviews the critical issues facing renewed approaches to lowering the US rate of smoking. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous